It is becoming apparent that endogenous cannabinoids play an important modulatory role in the CNS, by acting as retrograde messengers in a number of brain regions, where they are produced postsynaptically from cell bodies and travel backwards onto presynaptic nerve terminals to activate cannabinoid CB 1 receptors and reduce neurotransmitter release. Retrograde endocannabinoid signalling is initiated by Ca 2+ influx subsequent to depolarisation of the postsynaptic neuron, and/or by activation of G q -coupled group I metabotropic glutamate receptors (mGluR) in numerous brain regions (for review see Chevaleyre et al., 2006) . In addition, activation of G q -coupled mAChRs has also been shown to initiate retrograde endocannabinoid signalling in the hippocampus and striatum (Fukudome et al., 2004; Kim et al., 2002; Narushima et al., 2006; Narushima et al., 2007; Ohno-Shosaku et al., 2003; Uchigashima et al., 2007) .
The PAG contains a dense plexus of cholinergic nerve terminals which arise from brain structures, such as the pontine tegmentum (e.g. Woolf et al., 1990) . Acetylcholine produces its physiological effects via ligand gated nicotinic cholinergic receptors (nAChRs) and a heterogeneous family of mAChRs. There are five subtypes of muscarinic GPCRs, including the M2 and M4 subtypes which couple via G i/o -proteins and the M1, M3 and M5 subtypes which couple via G q -proteins (Caulfield, 1993) . The midbrain PAG contains a range of nAChR and mAChR subtypes (e.g. Aubert et al., 1996; Yasuda et al., 1993) . Microinjection of cholinergic agonists into the PAG produces analgesia and associated behavioural actions which are mediated by both nAChRs and mAChRs (Guimaraes et al., 2000; Monassi et al., 1997) . Functional studies indicate that opioids and cannabinoids produce analgesia from within the PAG by reducing the inhibitory influence of GABAergic interneurons onto output neurons which form part of an endogenous descending MOL 45872, Page 5 analgesic pathway, a process known as disinhibition (Fields et al., 2006) . At the cellular level, opioids and cannabinoids inhibit GABAergic and glutamatergic synaptic transmission in the PAG via a presynaptic mechanism (Vaughan et al., 2000; Vaughan et al., 1997) . In the present study, we examined the effects of cholinergic receptor activation on GABAergic and glutamatergic synaptic transmission in the PAG and whether these effects were mediated by the endocannabinoid system. MOL 45872, Page 6
Materials and methods
Experiments were carried out on male and female Sprague-Dawley rats (14 -24 days old) under a protocol approved by the Royal North Shore Hospital/University of Technology Sydney Animal Care and Ethics Committee. Animals were anaesthetised with isoflurane, decapitated and the brain rapidly removed and placed into ice-cold artificial cerebrospinal fluid (ACSF) of composition (mM): NaCl 126, KCl 2.5, NaH 2 PO 4 1.4, MgCl 2 1.2, CaCl 2 2.4, glucose 11, NaHCO 3 25, equilibrated with 95 % O 2 and 5 % CO 2 . Coronal midbrain slices containing PAG were then cut (300 µm) using a vibratome (VT1000S, Leica Microsystems, Nussbloch, Germany), in ice-cold ACSF, as described previously (Vaughan et al., 2000) . The slices were maintained at 34 ˚C in a submerged chamber containing ACSF. The slices were then individually transferred to a recording chamber and superfused continuously (1.6 -1.8 ml.min , stimuli: 1 -40 V, 50 -300 µs) via unipolar glass or bipolar tungsten stimulating electrodes (tip separation = 50 µm) placed 20 -100 µm from the recording electrode. GABA A -receptor mediated IPSCs were obtained in the presence of the non-NMDA receptor antagonist, CNQX (5 µM) and the glycine receptor antagonist, strychnine (5 µM). Non-NMDA mediated EPSCs were obtained in the presence of picrotoxin (100 µM) and strychnine (5 µM). In some experiments, spontaneous miniature IPSCs were obtained in the presence of CNQX (5 µM), strychnine (5 µM) and the addition of tetrodotoxin (300 nM).
IPSCs and EPSCs were filtered (2 -5 kHz low-pass filter) and sampled (5 -10 kHz) for on-line and later offline analysis (Axograph X, Axograph Scientific Software, Sydney, Australia). Miniature IPSCs were sampled in 5 s epochs every 6 s for analysis and IPSCs above a preset threshold (4.5 -5.0 standard deviations above baseline noise) were automatically detected by a sliding template algorithm, then manually checked offline.
Plots of detected event frequency versus time and cumulative probability distributions of event amplitudes MOL 45872, Page 7 and inter-event intervals were constructed. Statistical comparisons between two groups were made using Student's paired t-tests, and those between more than two groups were made using a one-way analysis of variance (ANOVA) followed by post-hoc comparisons using the Newman-Keuls correction for multiple comparisons (Prism, Graphpad Software, San Diego, USA). Differences were considered significant when P < 0.05. Dose-response curves were constructed using a logistic function (Prism). All pooled data were expressed as means ± SEM. Superfusion of atropine (3 µM) alone, however, had no effect on the basal amplitude of evoked IPSCs (110 ± 5 % of control, P = 0.08, n = 6), or on the ratio of evoked IPSC 2 /IPSC 1 (97 ± 3 % of control, P = 0.4, n = 6).
Physostigmine and atropine had no effect on membrane current, or the conductance of the neurons at -65 mV. 
Cholinergic agonists inhibit GABAergic synaptic transmission via M1/M3 mAChR subtypes
We further examined the receptor subtypes involved in the effects of carbachol by pre-incubating slices in a range of cholinergic antagonists. In slices pre-incubated in atropine (3 µ M), carbachol (10 µM) had no effect on the amplitude of evoked IPSCs (Figure 5a , g, P = 0.8, n = 5). By contrast, carbachol produced a reduction in the amplitude of evoked IPSCs in slices pre-incubated with the nAChR antagonist mecamylamine (3 µM) (P < 0.0001, n = 5), which was not significantly different to the reduction produced by carbachol alone (Figure 5b , g, P > 0.05).
We then examined the effect of a range of subtype selective mAChR antagonists. In the presence of the M2 selective antagonist gallamine (100 µM), carbachol (10 µM) produced a reduction in the amplitude of evoked IPSCs (P = 0.01, n = 7), which was not significantly different to that produced by carbachol alone (Figure 5c , MOL 45872, Page 10 g, P > 0.05). In the presence of the M4 selective antagonist PD-102807 (500 nM), carbachol (10 µM) also produced a reduction in the amplitude of evoked IPSCs (P = 0.004, n = 5), which was not significantly different to that produced by carbachol alone (Figure 5d , g, P > 0.05). Carbachol (10 µM) also produced a reduction in the amplitude of evoked IPSCs in the presence of the M1/M3 selective antagonist, 4-DAMP (30 nM, P = 0.04, n = 5), and the M1 selective antagonist, pirenzepine (300 nM) (P = 0.03, n = 6), however this was significantly less than that produced by carbachol alone (Figure 5e , f, g, P < 0.001). These results suggest that the M1, and possibly the M3 mAChR receptors predominantly mediate the effects of muscarinic receptor activation in PAG.
Cholinergic inhibition of GABAergic transmission is mediated via endocannabinoids
Studies in the hippocampus and striatum have shown that M1/M3-induced suppression of synaptic transmission is mediated by retrograde endocannabinoid signalling. Recent evidence suggests that the endocannabinoid involved is 2-AG, which is produced via the phospholipase C/ DAG lipase pathway (Hashimotodani et al., 2007; Hashimotodani et al., 2005; Maejima et al., 2005; Melis et al., 2004; Newman et al., 2007; Uchigashima et al., 2007) . We therefore examined whether the M1/M3 induced effects on synaptic transmission in PAG are mediated by endocannabinoids. In the presence of the cannabinoid CB 1 receptor antagonist AM251 (3 µ M), carbachol (10 µM) produced a reduction in the amplitude of evoked IPSCs (P = 0.04, n = 7) which was significantly less than that produced by carbachol alone (Figure 6a , c, P < 0.001). The effect of carbachol was also occluded by the non-selective cannabinoid receptor agonist, HU210 (3 uM), with carbachol having no significant effect on the amplitude of evoked IPSCs in its presence (P = 0.05, n = 8). In addition, carbachol (3 -10 µM) did not produce a significant change in miniature IPSC rate in the presence of AM251 (3 µM) (rate = 81 ± 13 % of control, P = 0.2, n = 9). Physostigmine (100 µ M) also produced a reduction in the amplitude of evoked IPSCs in the presence of AM251 (P = 0.04, n = 5), which was significantly less than that produced by physostigmine alone (P = 0.008). In the presence of the DAG lipase inhibitor, tetrahydrolipstatin (10 µM), carbachol (10 µM) produced a reduction in the amplitude of evoked IPSCs (P = 0.006, n = 6) which was also significantly less than that produced by carbachol alone (Figure 6b , c, P < 0.001).
MOL 45872, Page 11
Since the carbachol induced inhibition of evoked IPSCs was not abolished by pirenzepine, AM251 or tetrahydrolipstatin, we examined whether the residual inhibition was mediated by presynaptic M2 mAChRs.
In the combined presence of gallamine (100 uM) and pirenzepine (300 nM), carbachol (10 µM) had no significant effect on the amplitude of evoked IPSCs (Figure 5g , P = 0.5, n = 6). Similarly, carbachol did not significantly affect evoked IPSC amplitude the presence of gallamine (100 uM) and either AM251 (3 µM) (P = 0.09, n = 5), or THL (10 µM) (Figure 6c , P = 0.06, n = 5).
Cholinergic inhibition of glutamatergic transmission is partly mediated via endocannabinoids
We finally examined whether carbachol also inhibited glutamatergic synaptic transmission in PAG via endocannabinoids. In the presence of picrotoxin (100 µM) and strychnine (5 µM), superfusion of carbachol (10 µM) produced a reduction in the amplitude of non-NMDA mediated evoked EPSCs which was reversed following addition of atropine (3 µM) (Figure 7a , e, P < 0.0001, n = 11) and was associated with an increase in the ratio of evoked EPSC 2 /EPSC 1 (P = 0.03). Carbachol (10 µM) produced a reduction in the amplitude of evoked EPSCs in the presence of AM251 (3 µM) (P = 0.005, n = 8) which was not significantly different to that produced by carbachol alone (Figure 7b , e, P > 0.05). Similarly, carbachol (10 µM) reduced the amplitude of evoked EPSCs in the presence of gallamine (100 µM) (P = 0.04, n = 6) and this was not significantly different to that produced by carbachol alone (Figure 7c , e, P > 0.05). By contrast, carbachol (10 µM) produced a reduction in the amplitude of evoked EPSCs in the combined presence of AM251 (3 µM) and gallamine (100 µM) (P = 0.04, n = 7) which significantly less than that produced by carbachol alone (Figure 7d , e, P < 0.05).
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Discussion
The present study has demonstrated that cholinergic agonists and endogenously released acetylcholine inhibit GABAergic and glutamatergic synaptic transmission within the PAG via activation of both M1 and M2 mAChRs. The M1 induced cholinergic inhibition appears to be indirectly mediated via endocannabinoids, produced via the phospholipase C/DAG lipase pathway, which activate presynaptic cannabinoid CB 1 receptors and subsequently decrease GABA and glutamate release from nerve terminals. These findings suggest that cholinergic actions within the PAG are, at least partly, mediated via the endocannabinoid signalling system.
A number of observations suggested that cholinergic agonists and endogenously released acetylcholine suppressed GABAergic and glutamatergic synaptic transmission via a presynaptic muscarinic mechanism. In the present study, the non-degradable cholinergic agonist carbachol caused a reduction in the amplitude of evoked GABA A mediated IPSCs and evoked non-NMDA mediated EPSCs which was associated with an increase in their paired-pulse ratios. This carbachol induced inhibition was reversed by the muscarinic antagonist atropine, but not by the nicotinic antagonist mecamylamine. Carbachol and the muscarinic agonist oxotremorine-M also produced a concentration-dependent reduction in the frequency, but not the amplitude of spontaneous miniature IPSCs and had no effect on the membrane conductance of neurons.
This muscarinic presynaptic inhibition of synaptic transmission is similar to that observed in other brain regions (Behrends and Ten Bruggencate, 1993; Bellingham and Berger, 1996; Fukudome et al., 2004; Li et al., 2004; Shen and Johnson, 2000) . It is also similar to that described previously for opioids and cannabinoids within the PAG (Vaughan et al., 2000; Vaughan et al., 1997) , both of which produce analgesia when injected into this brain structure (Fields et al., 2006) . While atropine alone had no effect on synaptic transmission, the acetylcholinesterase inhibitor physostigmine produced an atropine sensitive reduction in evoked IPSCs. This indicates that endogenously released acetylcholine can also inhibit GABAergic synaptic transmission within the PAG and tonically modulate analgesia, however, this appears to be normally suppressed by uptake and degradation, at least in the slice preparation.
Binding and immunohistochemical studies have shown that the M1, M2, M3 and M4 mAChR subtypes are present within the midbrain (e.g. Aubert et al., 1996; Yasuda et al., 1993) . In the present study, the carbachol MOL 45872, Page 13 induced inhibition of GABAergic transmission was significantly reduced by the M1 and M1/M3 antagonists pirenzepine and 4-DAMP, but not by the M2 and M4 antagonists, gallamine and PD-102807. Furthermore, complete suppression of carbachol's inhibitory effect was obtained in the combined presence of pirenzepine and gallamine. These results suggest that the mAChR induced inhibition of GABAergic transmission was largely mediated by the M1 receptor and possibly the M3 receptors, with a smaller M2 receptor contribution, similar to that previously observed in the hippocampus (Fukudome et al., 2004; Ohno-Shosaku et al., 2003) .
While gallamine also had no effect on the carbachol induced inhibition of glutamatergic transmission, M2 receptors were also likely to have a role in excitatory transmission (see below). The present findings differ to those in other brain regions where cholinergic inhibition of GABAergic and glutamatergic transmission is largely mediated exclusively by M1/M3 and M2 receptors, respectively (Bellingham and Berger, 1996; Li et al., 2004; Shen and Johnson, 2000) . It should be emphasised, however, that some of the antagonists used in the present and prior studies display modest selectivity (Caulfield, 1993) and the receptor subtypes involved would need to be verified by knocking out mAChR subtypes (e.g. Fukudome et al., 2004; OhnoShosaku et al., 2003) .
The observation that the cholinergic inhibition of GABAergic synaptic transmission was largely mediated by M1 mAChRs is interesting because, like group I mGluRs (mGluR1 and mGluR5), M1/M3/M5 mAChRs are G q -coupled receptors which act via the phospholipase C/diacylglycerol cascade (Caulfield, 1993) . It has previously been demonstrated that group I mGluR induced inhibition of GABAergic synaptic transmission is mediated indirectly via the endocannabinoid system in a number of brain regions (for review see Chevaleyre et al., 2006) , including the PAG (Drew et al., 2008) . Although studied to a lesser extent, M1/M3 mAChR activation also inhibits GABAergic synaptic transmission via an endocannabinoid dependent mechanism in the hippocampus and striatum (Fukudome et al., 2004; Narushima et al., 2006; Narushima et al., 2007; Ohno-Shosaku et al., 2003) . In the present study, the carbachol induced inhibition of evoked and miniature IPSCs was reduced by the cannabinoid CB 1 receptor antagonist AM251 and occluded by the pancannabinoid receptor agonist HU210, consistent with that previously observed in the hippocampus and striatum (Fukudome et al., 2004; Kim et al., 2002; Narushima et al., 2007; Ohno-Shosaku et al., 2003; Uchigashima et al., 2007) . The carbachol induced inhibition of evoked IPSCs was abolished in the combined presence of AM251 and gallamine. In addition, the carbachol induced inhibition of evoked EPSCs was MOL 45872, Page 14 reduced by AM251 and gallamine together, but not individually. Therefore it is likely that muscarinic inhibition of GABAergic and glutamatergic synaptic transmission within the PAG is mediated by parallel mechanisms, including indirect M1 mAChR-induced production endocannabinoids which activate presynaptic cannabinoid CB 1 receptors and direct presynaptic M2 mAChR activation. These findings are similar to those previously reported for acetylcholine, glutamate and serotonin which also modulate synaptic transmission via indirect G q -coupled endocannabinoid mechanisms and direct G i/o -coupled presynaptic inhibition in the PAG and other brain regions (Best and Regehr, 2008; Drew et al., 2008; Fukudome et al., 2004) . The present findings, however, differ to the striatum where muscarinic inhibition of GABAergic, but not glutamatergic synaptic transmission is mediated by endocannabinoids (Narushima et al., 2006) .
To date, two major endocannabinoids, anandamide and 2-arachidonylglycerol, have been identified which are biosynthesised via the phospholipase D and phospholipase C/DAG lipase pathways, respectively (for review see Pacher et al., 2006) . There is increasing evidence that 2-arachidonylglycerol mediates the M1/M3 mAChR and group I mGluR induced inhibition of synaptic transmission because it is abolished by phospholipase C and DAG lipase inhibitors, and by knocking out phospholipase Cβ (Hashimotodani et al., 2007; Hashimotodani et al., 2005; Maejima et al., 2005; Melis et al., 2004; Newman et al., 2007; Uchigashima et al., 2007) . While we did not examine the role of phospholipase C, it was found that the carbachol induced inhibition of evoked IPSCs was reduced by the DAG lipase inhibitor tetrahydrolipstatin to similar extent as that produced by AM251. This indicates that the phospholipase C/DAG lipase pathway is involved in the M1 mAChR-induced effects within the PAG, and supports the growing evidence suggesting that 2-AG, rather than anandamide is the endocannabinoid involved in M1/M3 mAChR-induced suppression of synaptic transmission.
Cannabinoids have a pivotal role in analgesia and anxiety in the PAG (Finn et al., 2003; Lichtman et al., 1996; Moreira et al., 2007) , and modulation of the endocannabinoid system represents a promising new target for the treatment of anxiety and pain, particularly within the PAG ( (Hohmann et al., 2005; Kathuria et al., 2003) . The functional effects of cholinergic agents within the PAG are largely mediated via the GABAergic system (Monassi et al., 1999) . It is thought that cannabinoids produce analgesia within the PAG in a similar fashion to µ -opioids, by indirectly reducing GABAergic transmission onto output neurons that form part of an endogenous descending analgesic system (Fields et al., 2006) . The present observation of MOL 45872, Page 15 endocannabinoid mediated presynaptic inhibition of GABAergic transmission by cholinergic agonists and endogenous acetylcholine is consistent with the analgesic and anxiolytic mechanism of action of cannabinoids and opioids in the descending system. Therefore, the present findings suggest that cholinergic induced analgesic and other behavioural effects within the PAG are at least partly mediated by endocannabinoid-dependent mechanisms. These findings also raise the possibility that like group 1 mGluRs, endocannabinoid signalling via M1/M3 mAChRs might occur in numerous brain regions. Ultimately, this will contribute to the growing number of studies suggesting that endocannabinoid signalling may be an important global phenomenon underlying cholinergic transmission within the brain. In (C) *, ** and *** denote significantly different from pre-carbachol values (P < 0.05, 0.01, 0.001). ## denotes significantly different between control and other pre-treatment groups (P < 0.01). Traces in (A -B) are from different neurons. Scale bars in (A -B) and are 100 pA and 10 ms. 
